[go: up one dir, main page]

UY28774A1 - Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes. - Google Patents

Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.

Info

Publication number
UY28774A1
UY28774A1 UY28774A UY28774A UY28774A1 UY 28774 A1 UY28774 A1 UY 28774A1 UY 28774 A UY28774 A UY 28774A UY 28774 A UY28774 A UY 28774A UY 28774 A1 UY28774 A1 UY 28774A1
Authority
UY
Uruguay
Prior art keywords
diabetes
treatment
heteroarilaminopirazol
derivatives
useful
Prior art date
Application number
UY28774A
Other languages
English (en)
Inventor
Joachim Rudolph
Steven Magnuson
Libing Chen
Chih-Yuan Chuang
Ning Qi
Philip Wickens
Alana Olague
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of UY28774A1 publication Critical patent/UY28774A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos heteroarilaminopirazólicos, a composiciones farmacéuticas y a métodos para el tratamiento de la diabetes y trastornos relacionados.
UY28774A 2004-02-27 2005-02-25 Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes. UY28774A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54833104P 2004-02-27 2004-02-27
US57290604P 2004-05-20 2004-05-20

Publications (1)

Publication Number Publication Date
UY28774A1 true UY28774A1 (es) 2005-08-31

Family

ID=34976070

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28774A UY28774A1 (es) 2004-02-27 2005-02-25 Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.

Country Status (17)

Country Link
US (2) US7517878B2 (es)
EP (1) EP1720863A4 (es)
JP (1) JP2007525513A (es)
KR (1) KR20060124727A (es)
AR (1) AR049418A1 (es)
AU (1) AU2005220723A1 (es)
BR (1) BRPI0508051A (es)
CA (1) CA2557527A1 (es)
EC (1) ECSP066883A (es)
IL (1) IL177232A0 (es)
MA (1) MA28479B1 (es)
NO (1) NO20064325L (es)
PE (1) PE20051159A1 (es)
RU (1) RU2006134004A (es)
TW (1) TW200538130A (es)
UY (1) UY28774A1 (es)
WO (1) WO2005086656A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
WO2006065590A2 (en) * 2004-12-16 2006-06-22 Xtl Biopharmaceuticals Inc. Pyridine and pyrimidine antiviral compositions
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
ES2535854T3 (es) * 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
PL2013204T3 (pl) 2006-03-24 2015-09-30 Array Biopharma Inc Analogi 2-aminopirydyny jako aktywatory glukokinazy
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
WO2008118718A2 (en) * 2007-03-23 2008-10-02 Array Biopharma Inc. 2-aminopyridine analogs as glucokinase activators
CA2683152A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
BRPI0816881A2 (pt) 2007-09-21 2015-03-17 Array Biopharma Inc Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
US9315449B2 (en) * 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
EP2135865A1 (de) 2008-06-17 2009-12-23 Bayer CropScience AG Substituierte 1-(Diazinyl) pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
EP2194052A1 (de) 2008-12-06 2010-06-09 Bayer CropScience AG Substituierte 1-(Thiazolyl)- und 1-(Isothiazolyl)pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
RU2017109664A (ru) * 2009-10-06 2019-01-23 Милленниум Фармасьютикалз, Инк. Гетероциклические соединения, используемые в качестве ингибиторов pdk1
WO2011073098A1 (de) 2009-12-15 2011-06-23 Bayer Cropscience Ag 1-(heteroaryl)-pyrazol-4-yl-essigsäuren, verfahren zu deren herstellung und deren verwendung als herbizide und pflanzenwachstumsregulatoren
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
US20170291890A1 (en) * 2014-09-17 2017-10-12 Epizyme, Inc. Heterocycle substituted amino-pyridine compounds and methods of use thereof
WO2016092559A1 (en) * 2014-12-12 2016-06-16 Oat & Iil India Laboratories Private Limited Substituted pyrazole derivatives having activity as fungicides
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
KR101725292B1 (ko) 2016-03-30 2017-04-10 한국과학기술연구원 항암 활성을 갖는 신규 피리미딘-4-카르복시산 유도체
PE20190395A1 (es) 2016-06-16 2019-03-13 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405207A1 (de) * 1994-02-18 1995-08-24 Bayer Ag N-Pyrazolylaniline und N-Pyrazolylaminopyridine
US20020103185A1 (en) * 2000-08-31 2002-08-01 Sanner Mark A. Pyrazole derivatives
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7319102B1 (en) * 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors

Also Published As

Publication number Publication date
TW200538130A (en) 2005-12-01
US20090209451A1 (en) 2009-08-20
ECSP066883A (es) 2006-11-24
CA2557527A1 (en) 2005-09-22
JP2007525513A (ja) 2007-09-06
US7517878B2 (en) 2009-04-14
WO2005086656A2 (en) 2005-09-22
AR049418A1 (es) 2006-08-02
NO20064325L (no) 2006-11-22
MA28479B1 (fr) 2007-03-01
EP1720863A4 (en) 2009-04-22
AU2005220723A1 (en) 2005-09-22
KR20060124727A (ko) 2006-12-05
PE20051159A1 (es) 2006-02-22
RU2006134004A (ru) 2008-04-10
WO2005086656A3 (en) 2005-12-29
US20050192294A1 (en) 2005-09-01
BRPI0508051A (pt) 2007-07-17
IL177232A0 (en) 2006-12-10
EP1720863A2 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
UY28473A1 (es) Nuevos compuestos
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
EA201070786A1 (ru) Бензофуропиримидиноны
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2007003049A1 (es) Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
IL195030A (en) Dpp iv inhibitor formulations
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CL2007003758A1 (es) Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer.
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
NO20082096L (no) Azaindol-2-karboksamidderivativer
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TW200626158A (en) Naphthaline derivatives
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
CR10036A (es) Procedimientos para la preparación de derivados de ciclopropilamida
WO2006077024A3 (en) 5-aminoindole derivatives

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160428